تداخلات داونوروبيسين

Daunorubicin hydrochloride should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or daunorubicin hydrochloride. (نشرة داونوروبيسين، التداخلات الدوائية)

In a clinical trial, the first two patients given high-dose cytarabine (2 g/m 2 per day) by continuous infusion with daunorubicin and bortezomib for relapsed acute myelogenous leukemia died of ARDS early in the course of therapy. (نشرة بورتيزوميب، التحذيرات والاحتياطات)

Anthracycline Antibiotics High doses of cyclosporine (e.g., at starting intravenous dose of 16 mg/kg/day) may increase the exposure to anthracycline antibiotics (e.g., doxorubicin, mitoxantrone, daunorubicin) in cancer patients. (نشرة سيكلوسبورين، التداخلات الدوائية)

Cyclophosphamide used concurrently with daunorubicin hydrochloride may also result in increased cardiotoxicity. (نشرة داونوروبيسين، التداخلات الدوائية)

Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (نشرة ميتوكسانترون، التحذيرات)

Hepatotoxic medications, such as high-dose methotrexate, may impair liver function and increase the risk of toxicity. (نشرة داونوروبيسين، التداخلات الدوائية)